Levobetaxolol

Summary

Levobetaxolol (CHEMBL1201274) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 307.4 Da · C18H29NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201274
Name	Levobetaxolol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	60657
ChEBI	CHEBI:59254
Molecular formula	C18H29NO3
Molecular weight	307.4
InChIKey	NWIUTZDMDHAVTP-KRWDZBQOSA-N

SMILES: CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O

IUPAC name: (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol

ChEBI definition: The (S)-enantiomer of betaxolol.

Also known as: Betaxolol, (s)-, Levobetaxolol, LEVOBETAXOLOL, Levobetaxolol hydrochlorideÊ, Levobetaxolol hydrochlorideÂ, MMV1646424, levobetaxolol

Parent form; salt/anhydrous children: CHEMBL1200837

Patent coverage: 5,846 distinct patent families (23,799 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-1 adrenergic receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P18090	8.3	Kd	5.01	nM	CHEMBL_ACT_1017045

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).